Aptose Biosciences Inc.

Aptose Biosciences Inc. is a clinical-stage biotechnology company dedicated to developing precision medicines for life-threatening cancers, with a primary focus on hematologic malignancies. The company's mission involves advancing first-in-class targeted agents to address unmet medical needs in oncology. Aptose maintains executive headquarters in Toronto, Canada, with principal executive offices located in San Diego, California.

The company's pipeline features small molecule cancer therapeutics designed to offer single-agent efficacy and to enhance the effectiveness of existing anti-cancer therapies without introducing overlapping toxicities. Key investigational products include tuspetinib, an oral, potent myeloid kinase inhibitor, and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor. Both drug candidates are in clinical trials for various hematologic malignancies, such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and B-cell malignancies. Tuspetinib is currently undergoing Phase 1/2 clinical trials for relapsed or refractory AML and is also being developed as a frontline triplet therapy for newly diagnosed AML. Luxeptinib is in Phase 1a/b trials for B-cell malignancies and relapsed/refractory AML and high-risk MDS.

Dr. William G. Rice serves as the Chairman, President, and CEO of Aptose Biosciences Inc. Recent corporate developments include the approval by shareholders in March 2026 of a "go private" transaction, under which Hanmi Pharmaceutical Co. Ltd. will acquire all outstanding shares of Aptose not already owned by Hanmi. Hanmi Pharmaceutical has provided significant financial support to Aptose. In June 2026, the CEO provided a short-term cash advance to support immediate operational needs, as the company actively seeks additional funding, noting potential insolvency risks if further capital is not secured. Despite these financial challenges, recent clinical data from the TUSCANY Phase 1/2 trial for tuspetinib triplet therapy in newly diagnosed AML patients have shown promising safety, response, and MRD data.